Evidence map›Paper›PMID 30124995›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2020

Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.

Li Lv, Fang Wang, Liang Wu, Jin-Wei Wang, Zhao Cui, Salim S Hayek, Changli Wei, Jochen Reiser, Kevin He, Luxia Zhang and 2 more

Registry-linked trialOpen access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03041987 (Chinese Cohort Study of Chronic Kidney Disease), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03041987 active not recruitingnot on this map

Chinese Cohort Study of Chronic Kidney Disease

TypeobservationalSponsorPeking University First HospitalRan2012 to 2026Enrolled5,000ConditionsRenal Insufficiency, ChronicArmsDemographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Association of suPAR, ST2, and galectin-3 with eGFR decline and mortality in patients with advanced heart failure with reduced ejection fraction.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2024
    Article
  3. Article
  4. The Perspective of Vitamin D on suPAR-Related AKI in COVID-19.International journal of molecular sciences · 2022
    Review
  5. suPAR: An Inflammatory Mediator for Kidneys.Kidney diseases (Basel, Switzerland) · 2022
    Review
  6. Review
  7. Article
  8. Observational
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Li LvRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Fang WangRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Liang WuRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Jin-Wei WangRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Zhao CuiRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Salim S HayekDepartment of Medicine, Rush University Medical Center, Chicago, IL, USA.
Changli WeiDepartment of Medicine, Rush University Medical Center, Chicago, IL, USA.
Jochen ReiserDepartment of Medicine, Rush University Medical Center, Chicago, IL, USA.
Kevin HeDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Luxia ZhangRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Min ChenRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Ming-Hui ZhaoRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Peking University · CNPeking University First Hospital · CNRush University Medical Center · USUniversity of Michigan–Ann Arbor · US

Funding

The KIDCOV Study: Assessment of Kidney Injury and Associated Risk Factors for SARS-CoV-2R01DK109720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI REISER, JOCHEN, SARWAL, MINNIE M · 2017 to 2021
$3.2M
Role of Circulating suPAR in FSGSR01DK101350 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI REISER, JOCHEN · 2013 to 2017
$2.6M
Role of SuPAR in the Intersection between Cardiovascular and Kidney DiseaseR01HL153384 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HAYEK, SALIM · 2020 to 2024
$2.5M
NHLBI NIH HHS R01 HL153384NIDDK NIH HHS R01 DK101350NIDDK NIH HHS R01 DK109720
6 · The paper itself

Abstract

backgroundSoluble urokinase-type plasminogen activator receptor (suPAR), a marker of immune activation, was shown to be associated with outcomes and kidney disease among various patient populations. The prognostic role of circulating suPAR levels in patients with chronic kidney disease (CKD) needs to be investigated in a cohort with large sample size of renal diseases.

methodsWe measured serum suPAR concentration in 2391 CKD patients in the multicenter Chinese Cohort Study of Chronic Kidney Disease, and investigated the association of serum suPAR with the prespecified endpoint event, end-stage renal disease (ESRD), using Cox proportional hazards regression model.

resultsAltogether, 407 ESRD events occurred during the median follow-up of 54.8 (interquartile range: 47.5-62.2) months. The higher levels of serum suPAR were independently associated with increased risk of incident ESRD after adjusting for potential confounders including the baseline estimated glomerular filtration rate categories, with the hazard ratios (HRs) of 1.53 [95% confidence intervals (CIs) 1.10-2.12] for the top tertile (≥3904 pg/mL) compared with the bottom tertile (<2532 pg/mL). When stratified by the etiologies of CKD, among patients with glomerulonephritis (GN), serum suPAR levels were also independently associated with the higher risk of ESRD, with an HR of 1.61 (95% CI 1.03-2.53) in the top tertile compared with the bottom tertile.

conclusionsCirculating suPAR level was independently associated with an increased risk of progression to ESRD in Chinese CKD patients, especially in those with an etiology of GN.

Indexed as

AdultBiomarkersChinaDisease ProgressionFemaleGlomerular Filtration RateHumansIncidenceKidney Failure, ChronicMaleMiddle AgedPrognosisProspective StudiesReceptors, Urokinase Plasminogen ActivatorRenal Insufficiency, ChronicBiomarkersPLAUR protein, humanReceptors, Urokinase Plasminogen Activatorchronic kidney diseaseESRDoutcomesprospective studysuPAR

Identifiers

PMID30124995
PMCPMC9214641
OpenAlexW2885840422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.